203 related articles for article (PubMed ID: 10606233)
1. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.
Kato S; Shimada A; Osada M; Ikawa S; Obinata M; Nakagawara A; Kanamaru R; Ishioka C
Cancer Res; 1999 Dec; 59(23):5908-11. PubMed ID: 10606233
[TBL] [Abstract][Full Text] [Related]
2. Differential recognition of response elements determines target gene specificity for p53 and p63.
Osada M; Park HL; Nagakawa Y; Yamashita K; Fomenkov A; Kim MS; Wu G; Nomoto S; Trink B; Sidransky D
Mol Cell Biol; 2005 Jul; 25(14):6077-89. PubMed ID: 15988020
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers.
Hagiwara K; McMenamin MG; Miura K; Harris CC
Cancer Res; 1999 Sep; 59(17):4165-9. PubMed ID: 10485447
[TBL] [Abstract][Full Text] [Related]
4. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
5. p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate.
Kunisaki R; Ikawa S; Maeda T; Nakazaki Y; Kurita R; Harata M; Shutoh Y; Bai YS; Soda Y; Tanabe T; Dohi T; Kato R; Ikawa Y; Asano S; Tani K
J Gene Med; 2006 Sep; 8(9):1121-30. PubMed ID: 16832836
[TBL] [Abstract][Full Text] [Related]
6. Regulatory domain of protein stability of human P51/TAP63, a P53 homologue.
Osada M; Inaba R; Shinohara H; Hagiwara M; Nakamura M; Ikawa Y
Biochem Biophys Res Commun; 2001 May; 283(5):1135-41. PubMed ID: 11355891
[TBL] [Abstract][Full Text] [Related]
7. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
8. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences.
Shimada A; Kato S; Enjo K; Osada M; Ikawa Y; Kohno K; Obinata M; Kanamaru R; Ikawa S; Ishioka C
Cancer Res; 1999 Jun; 59(12):2781-6. PubMed ID: 10383130
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer.
Sunahara M; Shishikura T; Takahashi M; Todo S; Yamamoto N; Kimura H; Kato S; Ishioka C; Ikawa S; Ikawa Y; Nakagawara A
Oncogene; 1999 Jun; 18(25):3761-5. PubMed ID: 10391684
[TBL] [Abstract][Full Text] [Related]
10. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
[TBL] [Abstract][Full Text] [Related]
11. Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes.
Harmes DC; Bresnick E; Lubin EA; Watson JK; Heim KE; Curtin JC; Suskind AM; Lamb J; DiRenzo J
Oncogene; 2003 Oct; 22(48):7607-16. PubMed ID: 14576823
[TBL] [Abstract][Full Text] [Related]
12. Absence of p51 alteration in human ovarian cancer.
Shinozaki H; Okamoto A; Shimizu K; Saito M; Yokota J; Ochiai K
Int J Oncol; 2001 Mar; 18(3):549-52. PubMed ID: 11179485
[TBL] [Abstract][Full Text] [Related]
13. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.
Greenblatt MS; Beaudet JG; Gump JR; Godin KS; Trombley L; Koh J; Bond JP
Oncogene; 2003 Feb; 22(8):1150-63. PubMed ID: 12606942
[TBL] [Abstract][Full Text] [Related]
14. p51A (TAp63gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation.
Katoh I; Aisaki KI; Kurata SI; Ikawa S; Ikawa Y
Oncogene; 2000 Jun; 19(27):3126-30. PubMed ID: 10871867
[TBL] [Abstract][Full Text] [Related]
15. Derivation of the consensus DNA-binding sequence for p63 reveals unique requirements that are distinct from p53.
Ortt K; Sinha S
FEBS Lett; 2006 Aug; 580(18):4544-50. PubMed ID: 16870177
[TBL] [Abstract][Full Text] [Related]
16. Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia.
Yamaguchi H; Inokuchi K; Sakuma Y; Dan K
Leukemia; 2001 Nov; 15(11):1729-34. PubMed ID: 11681414
[TBL] [Abstract][Full Text] [Related]
17. p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm.
Perez CA; Ott J; Mays DJ; Pietenpol JA
Oncogene; 2007 Nov; 26(52):7363-70. PubMed ID: 17563751
[TBL] [Abstract][Full Text] [Related]
18. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development.
Wu G; Nomoto S; Hoque MO; Dracheva T; Osada M; Lee CC; Dong SM; Guo Z; Benoit N; Cohen Y; Rechthand P; Califano J; Moon CS; Ratovitski E; Jen J; Sidransky D; Trink B
Cancer Res; 2003 May; 63(10):2351-7. PubMed ID: 12750249
[TBL] [Abstract][Full Text] [Related]
19. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
Inga A; Monti P; Fronza G; Darden T; Resnick MA
Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes.
Lohrum M; Scheidtmann KH
Oncogene; 1996 Dec; 13(12):2527-39. PubMed ID: 9000127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
